Rhythm Pharmaceuticals (RYTM) Set to Announce Earnings on Tuesday

Rhythm Pharmaceuticals (NASDAQ:RYTM) will be posting its quarterly earnings results before the market opens on Tuesday, May 7th. Analysts expect Rhythm Pharmaceuticals to post earnings of ($2.12) per share for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last announced its quarterly earnings results on Thursday, February 22nd. The company reported ($0.70) EPS for the quarter, meeting the consensus estimate of ($0.70). Rhythm Pharmaceuticals had a negative net margin of 238.50% and a negative return on equity of 96.02%. The firm had revenue of $24.23 million during the quarter, compared to the consensus estimate of $25.38 million. During the same period last year, the firm earned ($0.75) EPS. The business’s quarterly revenue was up 175.7% compared to the same quarter last year. On average, analysts expect Rhythm Pharmaceuticals to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Rhythm Pharmaceuticals Price Performance

Shares of NASDAQ:RYTM opened at $43.76 on Friday. The firm has a fifty day moving average price of $40.97 and a two-hundred day moving average price of $39.47. Rhythm Pharmaceuticals has a one year low of $15.50 and a one year high of $52.57.

Insider Buying and Selling

In related news, CFO Hunter C. Smith sold 15,515 shares of Rhythm Pharmaceuticals stock in a transaction on Tuesday, March 19th. The shares were sold at an average price of $39.22, for a total value of $608,498.30. Following the transaction, the chief financial officer now owns 97,939 shares in the company, valued at approximately $3,841,167.58. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, CFO Hunter C. Smith sold 15,515 shares of Rhythm Pharmaceuticals stock in a transaction on Tuesday, March 19th. The shares were sold at an average price of $39.22, for a total value of $608,498.30. Following the transaction, the chief financial officer now owns 97,939 shares in the company, valued at approximately $3,841,167.58. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Yann Mazabraud sold 1,594 shares of Rhythm Pharmaceuticals stock in a transaction on Monday, February 12th. The stock was sold at an average price of $51.38, for a total transaction of $81,899.72. Following the completion of the transaction, the executive vice president now owns 7,702 shares in the company, valued at approximately $395,728.76. The disclosure for this sale can be found here. Insiders have sold a total of 172,069 shares of company stock worth $7,626,355 in the last 90 days. 4.70% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

RYTM has been the topic of several research reports. The Goldman Sachs Group raised their price objective on shares of Rhythm Pharmaceuticals from $42.00 to $52.00 and gave the company a “buy” rating in a research report on Thursday, January 25th. Needham & Company LLC restated a “buy” rating and set a $50.00 price objective on shares of Rhythm Pharmaceuticals in a research report on Friday, April 26th. Finally, Wells Fargo & Company lowered their price objective on shares of Rhythm Pharmaceuticals from $53.00 to $52.00 and set an “overweight” rating on the stock in a research report on Thursday, April 18th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $47.20.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.